$12.55 Million in Sales Expected for Bicycle Therapeutics Limited (NASDAQ:BCYC) This Quarter

Analysts expect that Bicycle Therapeutics Limited (NASDAQ:BCYC) will post $12.55 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Bicycle Therapeutics’ earnings. The lowest sales estimate is $1.25 million and the highest is $30.00 million. The firm is scheduled to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Bicycle Therapeutics will report full year sales of $16.27 million for the current financial year, with estimates ranging from $5.00 million to $30.00 million. For the next fiscal year, analysts anticipate that the business will post sales of $6.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Bicycle Therapeutics.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Tuesday, March 10th. The company reported ($0.25) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.27. Bicycle Therapeutics had a negative net margin of 221.78% and a negative return on equity of 56.13%. The business had revenue of $5.28 million during the quarter, compared to the consensus estimate of $0.80 million.

A number of research analysts recently issued reports on the stock. Canaccord Genuity assumed coverage on shares of Bicycle Therapeutics in a research report on Thursday, March 12th. They set a “buy” rating and a $23.50 target price for the company. Zacks Investment Research upgraded shares of Bicycle Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Friday, March 13th. Finally, BidaskClub upgraded shares of Bicycle Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, March 6th. Seven investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $19.08.

NASDAQ BCYC traded down $1.78 on Tuesday, reaching $12.77. 17,147 shares of the company’s stock traded hands, compared to its average volume of 26,439. The firm has a market cap of $203.50 million and a price-to-earnings ratio of -4.61. The stock has a 50 day moving average price of $13.74 and a 200-day moving average price of $10.67. Bicycle Therapeutics has a fifty-two week low of $6.24 and a fifty-two week high of $19.79.

An institutional investor recently bought a new position in Bicycle Therapeutics stock. Point72 Asset Management L.P. bought a new stake in shares of Bicycle Therapeutics Limited (NASDAQ:BCYC) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 382,499 shares of the company’s stock, valued at approximately $3,607,000. Point72 Asset Management L.P. owned 2.16% of Bicycle Therapeutics at the end of the most recent reporting period. 33.36% of the stock is owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Read More: Circuit Breakers

Get a free copy of the Zacks research report on Bicycle Therapeutics (BCYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.